Today: 4 February 2026
Subscribe
Browse Category

NASDAQ:IXHL News 4 December 2025 - 15 December 2025

Incannex Healthcare (NASDAQ: IXHL) Stock: FDA Fast Track Catalyst, Nasdaq Compliance Clock, and the Latest Forecasts as of Dec. 15, 2025

Incannex Healthcare (NASDAQ: IXHL) Stock: FDA Fast Track Catalyst, Nasdaq Compliance Clock, and the Latest Forecasts as of Dec. 15, 2025

Incannex Healthcare Inc. (NASDAQ: IXHL) is back on traders’ radar heading into mid-December, with the stock hovering around $0.42 in early Monday pricing on December 15, 2025, after closing near $0.40 in the prior session. The renewed attention isn’t coming out of nowhere. Over the past several weeks, Incannex has stacked up a series of developments that matter to speculative…
15 December 2025
·····
Incannex Healthcare (IXHL) Stock Soars on FDA Fast Track: December 2025 Outlook, Forecast & Key Risks

Incannex Healthcare (IXHL) Stock Soars on FDA Fast Track: December 2025 Outlook, Forecast & Key Risks

Incannex Healthcare Inc. (Nasdaq: IXHL) is back on traders’ radar after the U.S. Food and Drug Administration granted Fast Track designation to its lead sleep-apnoea drug candidate, IHL‑42X. The move caps a busy 2025 that also brought strong Phase 2 data in sleep apnoea and psilocybin-assisted therapy, a major clean-up of warrant overhang, and a fight to keep the company’s…
4 December 2025
·····

Stock Market Today

  • Actinogen Medical and Top ASX Penny Stocks Show Potential Amid Market Headwinds
    February 4, 2026, 3:40 PM EST. The Australian stock market faces pressure from a Reserve Bank rate hike and international tech sell-offs, with ASX 200 futures hinting at a downturn. Yet, ASX penny stocks continue to offer investment opportunities due to their low price points and growth potential. Actinogen Medical (ASX:ACW), a pre-revenue biotechnology firm valued at A$153.2 million, is advancing its Alzheimer's treatment trial and recently secured A$17 million in funding. Despite current unprofitability, Actinogen's innovative approach could spur future revenue growth. Brisbane Broncos Limited (A$181.38 million market cap) operates debt-free in sports management, underlining stability. These stocks exemplify how smaller firms with strong fundamentals may thrive even amid broader market uncertainty.
Go toTop